- Home
- INMB vs LITS Comparison
INMB vs LITS Comparison
Compare INMB & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | LITS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.4M | 44.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMB | LITS |
|---|---|---|
| Price | $1.59 | $1.16 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | ★ 364.9K | 309.2K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $0.95 |
| 52 Week High | $11.64 | $3.03 |
Technical Indicators
Market Signals| Indicator | INMB | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 47.57 |
| Support Level | $1.38 | $1.13 |
| Resistance Level | $1.71 | $1.16 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 54.17 | 29.61 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.